Ceruletide: Synthetic CCK Analog for Pancreatic Function Research

Principle Overview: Ceruletide as a Biochemical Tool in Digestive Research

Ceruletide (also known as caerulein or cerulein) is a synthetic decapeptide analog of cholecystokinin (CCK), mirroring its structure and biological function. As a potent CCK receptor agonist, ceruletide stimulates gastric, pancreatic, and biliary secretions and induces gastrointestinal smooth muscle contraction. These properties have made it indispensable for pancreatic function research, gastrointestinal physiology studies, and digestive disorder research, as it enables targeted activation of the cholecystokinin signaling pathway in both in vitro and in vivo models. Ceruletide from APExBIO (SKU B8465) is renowned for its high purity (>98%), water solubility, and batch-to-batch consistency, ensuring robust and reproducible results in gastrointestinal hormone research and pancreatic secretion pathway analysis.

Structurally, ceruletide is composed of the decapeptide sequence {pGlu}-Gln-Asp-Tyr(SO3H)-Thr-Gly-Trp-Met-Asp-Phe-NH2 (C₅₈H₇₃N₁₃O₂₁S₂; MW: 1352.40). Its solubility profile—insoluble in ethanol, but highly soluble in water (≥2.85 mg/mL with ultrasonic assistance) and DMSO (≥32 mg/mL)—offers flexibility for diverse experimental setups, from cell-based assays to animal models.

Step-by-Step Workflow: Protocols for Pancreatic and GI Physiology Studies

1. Reagent Preparation

• Stock Solution: Dissolve ceruletide in sterile water or DMSO to desired concentrations (suggested stock: 1–10 mM in DMSO; for water, ≥2.85 mg/mL with sonication). Filter sterilize using a 0.22 µm filter for cell culture applications.
• Aliquot and Storage: Dispense into single-use aliquots and store at -20°C. Avoid repeated freeze-thaw cycles to maintain peptide stability and bioactivity.

2. In Vitro Assays

• Pancreatic Acinar Cell Stimulation: Treat isolated rodent or human acinar cells with ceruletide (10–100 nM) to induce digestive enzyme secretion (e.g., amylase, trypsinogen). Collect supernatants at defined intervals for ELISA or spectrophotometric analysis.
• Gastrointestinal Smooth Muscle Contraction Assay: Incubate tissue strips (e.g., guinea pig ileum) in organ baths with incremental concentrations of ceruletide (1–100 nM). Record contractile responses using force transducers for quantification of CCK receptor-mediated contraction.

3. In Vivo Models

• Acute Pancreatitis Induction: Administer ceruletide intraperitoneally in rodents (e.g., 50 µg/kg/hour for 6–12 hours) to model acute pancreatitis and study downstream inflammatory and fibrotic pathways. Collect tissue and serum for histopathology and cytokine profiling.
• Gastrointestinal Motility Assay: Inject ceruletide in mice or rats and measure transit times using dye or radiolabelled markers. This supports assessment of GI smooth muscle contraction pathways and cholecystokinin analog efficacy.

4. Protocol Enhancements

• Use APExBIO’s validated protocols for consistent dosing and timing based on published standards (see workflow details).
• For multiplexed readouts, combine ceruletide stimulation with immunofluorescence or flow cytometry for cell viability, proliferation, and cytotoxicity endpoints (complementary scenario-driven guidance).

Advanced Applications and Comparative Advantages

1. Induction and Study of Pancreatic Fibrosis

Ceruletide is the gold-standard agent for inducing pancreatitis and subsequent fibrosis in rodent models. Its reproducible activation of the CCK receptor signaling cascade reliably initiates acinar cell injury, macrophage infiltration, and fibrotic gene expression, mirroring key features of chronic pancreatitis seen in humans. This makes it an essential control and induction agent in studies seeking to test antifibrotic interventions, such as the recent exploration of mesenchymal stem cell (MSC)-derived therapies targeting the MFGE8-dependent ANXA1-SMAD2/3 axis (Wangcheng Xie et al., 2026).

For example, in the referenced multimodal study, ceruletide-induced pancreatic injury provided a robust platform for evaluating the efficacy of umbilical cord-derived MSCs and extracellular vesicles (EVs) in ameliorating pancreatic fibrosis. The consistency and predictability of ceruletide’s effects directly supported mechanistic insights into regenerative medicine approaches for digestive disease.

2. GI Smooth Muscle Contraction and Motility Studies

As a potent gastrointestinal hormone analog, ceruletide is unmatched in its ability to elicit smooth muscle contraction via CCK receptor activation. This enables detailed mapping of contraction pathways, dose-response analyses, and comparative studies of novel CCK analogs or antagonists. The high solubility in water and DMSO further enables flexible assay design, including high-throughput screening for GI motility modulators.

3. Comparative Product Advantages

• Reproducibility: APExBIO’s ceruletide demonstrates >98% purity (HPLC and mass spectrometry validated), supporting consistent results across independent experiments (complements with purity-focused analysis).
• Solubility: Ready dissolution in aqueous and organic solvents allows for diverse experimental formats, from cell culture to organ bath and in vivo injection.
• Performance: In contraction assays, ceruletide yields robust, concentration-dependent increases in force (typically 2- to 6-fold over baseline at 10–100 nM), facilitating sensitive detection of functional changes in GI and pancreatic tissue.

Troubleshooting and Optimization Tips

Common Issues and Solutions

• Solubility Concerns: If difficulties arise dissolving ceruletide in water, apply gentle sonication and warm the solution to 37°C. For stock solutions, DMSO provides superior solubility (≥32 mg/mL).
• Peptide Degradation: Avoid repeated freeze-thaw cycles and use freshly prepared aliquots. For long-term stability, store at -20°C in tightly sealed vials, protected from light and moisture.
• Inconsistent Biological Response: Confirm peptide integrity by HPLC or mass spectrometry if batch variation is suspected. Always use APExBIO’s validated lots for reliable performance.
• Assay Sensitivity: Optimize dose and timing for each model system. For acute pancreatitis, titrate from 20–50 µg/kg/hour and adjust based on animal strain and desired severity. For smooth muscle assays, validate contractile response with positive and negative controls.
• Off-Target Effects: Minimize DMSO concentration in working solutions (<0.1% v/v) to prevent solvent-induced artifacts in cell-based assays.
• Multiplexed Endpoints: When combining with cytotoxicity or viability assays, ensure sequential, non-overlapping readouts to prevent signal interference (see scenario-based Q&A).

Optimizing Data Quality

• Use internal standards and replicate controls to assess assay reproducibility.
• For secretion assays, calibrate ELISA or colorimetric kits to the expected range of enzyme release following ceruletide treatment.
• In animal models, randomize treatment groups and employ blinded endpoint assessment to reduce bias.

Future Outlook: Expanding Horizons in Digestive and Fibrotic Disease Research

The versatility of ceruletide as a peptide hormone analog continues to drive innovation in gastrointestinal disorder models, from acute pancreatitis to chronic fibrotic syndromes. Its centrality in experimental workflows is exemplified by its use in the referenced study (Wangcheng Xie et al., 2026), where ceruletide served as both a disease inducer and a benchmark for evaluating advanced therapeutic strategies such as UCMSC-EVs and rhMFGE8 nanomedicine. As the landscape of regenerative medicine and drug delivery evolves, ceruletide-enabled models will underpin preclinical validation of next-generation antifibrotic agents and GI modulators.

For research teams seeking to dissect the CCK receptor signaling axis or quantify pancreatic and GI function, APExBIO’s Ceruletide remains a gold standard—offering unparalleled purity, solubility, and experimental versatility. Its adoption in digestive physiology studies, pancreatic fibrosis research, and motility assays is poised to accelerate discovery and translation in gastrointestinal hormone research for years to come.